Showing results (41-50 of 73) with videos related to
Sort By:
Pageof 8
Journal of Acquired Immune Deficiency Syndromes (1999)|August 6, 2009
Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infectionArkaitz Imaz, Sara Villar del Saz, M Angels Ribas, et al.The Journal of Antimicrobial Chemotherapy|January 23, 2015
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppressionMaria S Di Yacovo, José Moltó, Elena Ferrer, et al.European Journal of Internal Medicine|February 10, 2023
Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in SpainJordi Navarro, Adrian Curran, Berta Raventós, et al.Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 21, 2019
Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016Xavier Martínez-Gómez, Adrian Curran, Magda Campins, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 19, 2023
Impact of very early antiretroviral therapy during acute HIV infection on long-term immunovirological outcomesPaula Suanzes, Jordi Navarro, Ariadna Rando-Segura, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2011
Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in childrenJoaquin Burgos, Maria Peñaranda, Antoni Payeras, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 2, 2015
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial)Jose M Miro, Christian Manzardo, Elena Ferrer, et al.Atherosclerosis|September 29, 2012
LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudyMaria Saumoy, José Luis Sánchez-Quesada, Esteban Martínez, et al.JCI Insight|September 17, 2024
NKG2C and NKG2A coexpression defines a highly functional antiviral NK population in spontaneous HIV controlNerea Sánchez-Gaona, Ana Gallego-Cortés, Antonio Astorga-Gamaza, et al.Infectious Diseases and Therapy|February 19, 2024
Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World StudyJuan Ambrosioni, Natalia Anahí Díaz, Catia Marzolini, et al.Pageof 8